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Abstract
Introduction Patient registries, ‘organised systems that use observational methods to collect uniform data on a population 
defined by a particular disease, condition, or exposure, and that is followed over time’, are potentially valuable sources of 
data for supporting regulatory decision-making, especially for products to treat rare diseases. Nevertheless, patient registries 
are greatly underused in regulatory assessments. Reasons include heterogeneity in registry design and in the data collected, 
even across registries for the same disease, as well as unreliable data quality and data sharing impediments. The Patient 
Registries Initiative was established by the European Medicines Agency in 2015 to support registries in collecting data suit-
able to contribute to regulatory assessments, especially post-authorisation safety and effectiveness studies.
Methods We conducted a qualitative synthesis of the published observations and recommendations from an initiative-
led multi-stakeholder consultation and four disease-specific patient registry workshops. We identified the primary factors 
facilitating the use of registry data in regulatory assessments. We generated proposals on operational measures needed from 
stakeholders including registry holders, patients, healthcare professionals, regulators, marketing authorisation applicants 
and holders, and health technology assessment bodies for implementing these.
Results Ten factors were identified as facilitating registry use for supporting regulatory assessments of medicinal products. 
Proposals on operational measures needed for implementation were categorised according to three themes: (1) nature of 
the data collected and registry quality assurance processes; (2) registry governance, informed consent, data protection and 
sharing; and (3) stakeholder communication and planning of benefit-risk assessments.
Conclusions These are the first explicit proposals, from a regulatory perspective, on operational methods for increasing the 
use of patient registries in medicines regulation. They apply to registry holders, patients, regulators, marketing authorisation 
holders/applicants and healthcare stakeholders broadly, and their implementation would greatly facilitate the use of these 
valuable data sources in regulatory decision-making.
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1 Introduction
Health-related real world data provide crucial support for 
regulatory decision-making, especially in post-authorisation 
assessments of medicinal products [1]. There are multiple 
sources including patient (disease) registries, electronic 
health records, insurance claims databases, health surveys, 
and prescription dispensing databases [2]. Patient registries, 
‘organised systems that use observational methods to collect 
uniform data on a population defined by a particular disease, 
condition, or exposure, and that is followed over time’, are 
a potentially rich source of data, especially for evaluating 
the course of rare diseases and effects of new treatments 
[3–5]. Despite this, they are greatly underused in regulatory 
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335 products recommended for approval between 2005 and 
2013 by the main scientific committee of the European Med-
icines Agency (EMA), the Committee for Medicinal Prod-
ucts for Human Use (CHMP), 31 registries were requested 
to fulfil a condition of the marketing authorisation, but by 
December 2017, just ten had been completed [11]. Poten-
tially, registries could provide data permitting comparisons 
of outcomes from different treatments across different coun-
tries and healthcare settings over time as well as assessment 
of the impact of measures taken to minimise risks of medici-
nal products [12, 13]. Their limitations for such assessments 
are well-described, but a description of the features needed 
to encourage increased use is lacking [4, 12–14]. Our aim 
with this work was to provide proposals, from a regulatory 
perspective, on how registry stakeholders could fill this gap.
2  Methods
We conducted a qualitative synthesis of the observations 
and recommendations published in five reports arising from 
a multi-stakeholder consultation and four disease-specific 
workshops conducted as part of EMA’s Patient Registries 
Initiative.
From the consultation report, we identified the primary 
factors considered by stakeholders as facilitating the use of 
registry data for supporting medicines regulation.
From each of the four disease-specific workshop reports, 
we abstracted the participant observations and recommenda-
tions on utilising patient registry data in regulatory assess-
ments along with the measures needed from stakeholders 
in order to implement them. We then generated operational 
proposals, applicable to patient registries and stakeholder 
groups broadly, for implementing these measures.
3  Patient Registries Initiative
In 2015, EMA established a Patient Registries Initiative to 
support a systematic and standardised approach for registry 
contribution to medicines assessment, especially for post-
authorisation safety studies (PASS) and post-authorisation 
effectiveness studies (PAES) [6]. The initiative aims to cre-
ate a registry framework with collaboration between reg-
istry coordinators, including healthcare professionals’ and 
patients’ associations, academic institutions and national 
agencies responsible for overseeing healthcare services, and 
potential users of registry data, such as medicines regulators, 
reimbursement bodies, and pharmaceutical companies. Key 
elements of its strategy include facilitating the use of exist-
ing patient registries within the current legal and regulatory 
framework for medicinal products and providing methodo-
logical support for the establishment of new registries [15].
Key Points 
Patient registries are potentially valuable sources of data 
for supporting regulatory decision-making on medicines, 
but they are greatly underused owing to heterogeneity in 
registry design, the data collected and its quality, as well 
as to data sharing impediments.
The European Medicines Agency’s Patient Registries 
Initiative aims to support registries in collecting data 
suitable to contribute to regulatory assessments, espe-
cially post-authorisation safety and effectiveness studies.
We have generated operational proposals on patient reg-
istry data, quality assurance processes, governance and 
stakeholder communication that will help to increase the 
use of these valuable resources in regulatory benefit-risk 
assessments of medicines.
assessments of medicines. There are many reasons, includ-
ing heterogeneity in registry design within individual disease 
areas, unreliable data quality and data sharing barriers, all 
amplified by limited national and international collabora-
tion [5, 6].
1.1  Use of Patient Registries for Supporting 
Regulatory Assessments
In pivotal studies supporting marketing authorisation of 
medicinal products, randomised controlled trial (RCT) data 
are preferred by regulators. However, in situations where 
RCT data are limited or where RCTs are not ethical or are 
not feasible, as with many rare diseases, patient registry data 
may provide crucial support for regulatory decision-mak-
ing. For example, in the case of haemophilia, the updated 
guideline on Factor VIII products removes the obligation to 
perform clinical trials in previously untreated patients but 
requires post-authorisation studies based on a set of core 
data elements to be collected in patient registries [7]. For 
products granted conditional marketing approval, registry 
studies may provide post-authorisation data to fulfil regu-
lator-imposed specific obligations to confirm safety and/
or effectiveness, as is the case with the recently authorised 
chimeric antigen receptor (CAR) T-cell products, tiagenle-
cleucel and axicabtagene ciloleucel [8, 9]. Some registries 
may be of particular value in terms of the patient population 
size and representativeness, the duration of follow-up data 
for treatment-exposed patients and availability of informa-
tion not collected in other real world repositories.
Notwithstanding such potential, the under-use of patient 
registries in the regulatory context is striking [10, 11]. Of 
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4  Multi‑Stakeholder Consultation 
and Disease‑Specific Registry Workshops
At a consultation in October 2016, 122 expert stakeholders, 
including registry holders, patients, healthcare professionals, 
regulators, marketing authorisation holders and applicants 
(MAHs/MAAs), and health technology assessment (HTA) 
and reimbursement bodies, and European Commission rep-
resentatives shared their views on barriers to and facilita-
tors of registry use and on optimising the use of registries 
for regulatory assessments [16]. The discussions provided 
the groundwork for four disease-specific registry work-
shops held during 2017 and 2018 that explored the use of 
registry data for supporting regulatory assessments in four 
areas of active product development where new products 
had recently been approved or were undergoing assessment 
(Appendix Table 1, see the electronic supplementary mate-
rial): cystic fibrosis [17], multiple sclerosis [18], CAR T-cell 
therapies [19], and haemophilia therapies [20].
The four workshops together included 266 participants 
representing all of the stakeholder groups in each case. The 
individual workshop reports providing participants’ obser-
vations and recommendations, along with the report of the 
multi-stakeholder consultation, are published on the EMA 
patient registries webpage [6]. The objectives and methods 
of the individual patient registry workshops are described in 
Appendix Table 2 (see the electronic supplementary mate-
rial). This work did not require ethics approval.
5  Results
5.1  Factors Supporting the Use of Registries
Synthesis of the participant observations from the multi-
stakeholder consultation report generated a list of factors that 
facilitated the use of patient registries for regulatory assess-
ments. They included the use of common core data sets, 
common coding terminologies, complete data collection, 
especially on medications, facility for data access and shar-
ing, data linkage capacity, quality assurance processes and 
governance, early consideration of registries in the regulatory 
process, stakeholder communication, registry sustainability 
and the availability of a registry framework. Their value in 
facilitating registry use is described in Table 1. In each case, 
absence or incompleteness greatly impeded registry use.
5.2  Proposals on Operational Measures to Increase 
Registry Use in Regulatory Assessments
Three themes, generalisable to patient registries 
broadly, emerged from the published observations and 
recommendations made by the participants in each of the 
four disease-specific patient registry workshops:
1. Nature of the data collected and registry quality assur-
ance processes
2. Registry governance, informed consent, data protection 
and sharing
3. Stakeholder communication and planning of benefit-risk 
assessments.
5.2.1  Nature of the Data and Registry Quality Assurance 
Processes
The need for registries in a given disease area to collect core 
common data elements, commonly defined, was acknowl-
edged by all stakeholders as essential for ensuring that data 
from multiple registries in a given disease area could be 
combined to enhance both the generalisability and the power 
of studies that could be conducted using the data (Table 2, 
Box 1).   EMA scientific advice may assist in clarifying 
the suitability of individual registries for defined purposes 
[23]. Knowledge of data quality is fundamental for regula-
tory assessments. Quality may be judged according to three 
components: consistency, accuracy, and completeness. 
Table 2 defines each quality component, summarises poten-
tial indicators of quality that could be applied in registries, 
and describes the systems or solutions needed to facilitate 
these in operational terms. 
5.2.2  Registry Governance, Informed Consent, Data 
Protection and Sharing
Proposals are summarised in Table 3 for measures needed 
on registry governance, informed consents, and data sharing 
and protection in order to ensure that data are accessible for 
regulatory assessments and may be shared in the context of 
the applicable legal and governance frameworks.
Examples of recommendations from the individual work-
shop reports are quoted in Box 2. Registry sustainability 
measures were not a focus of the disease-specific workshop 
discussions given the regulatory context, but were acknowl-
edged by all stakeholders as crucial for registry stability and 
development.
5.2.3  Communication with Stakeholders
Acknowledged areas of improvements needed to support 
the use of registry data in regulatory assessments include 
communication between stakeholders early in the marketing 
authorisation process in order to plan for post-authorisation 
studies (Fig. 1, Box 3). The studies are needed so that mar-
keting authorisation, if granted, may be followed-up with 
timely evidence on the benefit-risk balance of new products 
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for patient and public health, most especially for products 
with specific obligations where delays in study completion 
are common [25–27]. Opportunities arise early in the mar-
keting authorisation process to pro-actively identify likely 
data needs, especially for post-authorisation studies. These 
opportunities are illustrated in Fig. 1. Where registry data 
could potentially contribute, there should be three-way con-
tact involving regulators, MAAs/MAHs and registry holders 
to explore data availability.
6  Discussion
6.1  Priorities for Implementation of Proposals
Our proposals have been synthesised from the published 
reports of a consultative discussion and four disease-specific 
workshops that together included almost 400 specialist stake-
holders with patient registry expertise. In doing so, we have 
leveraged the deep knowledge of participants in each disease 
area to generate proposals that apply to registries broadly. 
Implementation of the proposals by registry stakeholders 
collectively would help to establish a harmonised patient 
registry environment within many other individual disease 
areas, thereby increasing the suitability of registry data for 
regulatory assessments of related medicinal products.
From a regulatory perspective, the priorities for the devel-
opment of a European Union-wide framework on patient 
registries are:
• Availability of core common data sets, specific for indi-
vidual disease areas, with commonly defined data ele-
ments across registry networks
• Registry operational procedures for MAAs/MAHs and 
regulators to access data in accordance with national 
regulation and European General Data Protection Regu-
lation [20]
• Transparent quality assurance processes in registries.
Table 1  Factors facilitating registry use for supporting regulatory assessments
CHMP Committee for Medicinal Products for Human Use, EMA European Medicines Agency, MAAs/MAHs marketing authorisation applicants/
holders, PAES post-authorisation efficacy studies, PASS post-authorisation safety studies, PROs patient reported outcomes
Factor Value in supporting registry use for regulatory assessments
Use of common core data sets Collecting a common core set of data items with agreed definitions and data dictionaries increases the 
capacity to combine or pool data across patients or registries for regulatory assessments. Ideally, data 
items match regulatory needs. Capacity to collect additional data elements, even for a limited period, 
may be beneficial.
Common data coding terminologies The availability of coding terminologies such as the Medical Dictionary for Regulatory Activities 
 (MedDRA®) that could be used by all registries helps in facilitating the conduct of studies using data 
from multiple registries [21].
Complete information collection Complete information on critical disease variables is necessary. Medication information is often limited; 
primary disorder medication information is essential and should include the start and stop (where 
applicable) dates. Most registries do not record other medications, but some information is desirable. 
PROs are of increasing interest to stakeholders, but are not collected in most registries.
Data access and sharing Clear consent specifications on data use facilitate sharing of registry data with third parties including 
regulators and MAAs/MAHs. Data sharing and access are further determined by relevant national and 
European data protection legislation.
Data linkage capacity Linkages to external databases, for example, prescription dispensing, employment, or death registries 
add to the value of registry data, but linkages may be variable across member state.
Registry reporting, and quality assur-
ance processes and governance
Most registries have processes in place for annual reporting and for quality assurance including source 
data verification. While these are heterogeneous currently, they represent good baselines for further 
development in individual registries.
Timeliness of consideration Consideration of registry data in the authorisation process generally occurs when risk management plans 
and post-authorisation data needs are being discussed. Planning early in the authorisation process for 
registry use facilitates data access by reducing timelines for data upload from treating centres and for 
registry quality assurance processes.
Direct communication To best fulfil regulator-requested or regulator-imposed studies, regulators, MAAs/MAHs and registry 
holders need to communicate directly.
Sustainability Registry funding and support may be limited, causing difficulties in maintaining database systems, reli-
able quality assurance processes, and staff training. Data entry is often done on a voluntary basis and 
manually by clinical staff either directly or by importing information from electronic health records. 
Registry sustainability is crucial for long-term development.
Availability of a regulatory framework EMA guidelines and procedures for PASS and PAES provide a structure for stakeholder dialogue on 
registry use [22]. EMA scientific advice can support CHMP qualification opinions or advice on the 
suitability of a registry for undertaking pharmacoepidemiological studies [23].
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Therefore, in addressing the factors described in Table 1, 
the proposals on data elements, quality assurance, govern-
ance, patient consents, and data protection summarised in 
Tables 2 and 3, together with communication and planning 
early in the authorisation process, are critical if the potential 
of patient registry data for regulatory assessments of medici-
nal products is to be realised.
6.2  EMA Actions to Increase Registry Use
EMA has provided scientific advice to support CHMP quali-
fication opinions on two patient registries regarding their 
suitability for supporting regulatory assessments of medi-
cines, the European Cystic Fibrosis Society Patient Registry 
and the cellular therapy module of the European Blood and 
Table 2  Proposals on data elements and data quality attributes necessary in patient registries and on the operational measures required for imple-
mentation
HCPs healthcare professionals, PROs patient reported outcomes
Topic Proposals Operational measures required
Core common data elements Core common data elements to be collected by all 
contributing registries in a specific disease area
Agree on the core common data elements to be included 
in specific disease area registries, including the associ-
ated definitions and data dictionaries
Harmonise data element definitions across registries Provide data element definition information or source to 
stakeholders
Agree on core PROs that could feasibly be collected 
systematically
All stakeholders to collaborate on defining PROs (appro-
priate as necessary for patient age, capacity, language, 
and for caregivers)
Data quality Indicators on data consistency, accuracy and com-
pleteness to be implemented and reported
Registries to publish at agreed intervals reports or audits 
of data quality
Quality components Indicators of quality Operational measures required
Consistency:
 Uniformity of the data over 
time (e.g. laboratory data 
routinely entered)
Proportion of data fields changed over time
Proportion of fields missing over time
Audits and centre level data checks
Standard terminology and coding
Standard operating procedures
Registry data entry dashboard
Accuracy:
 Accuracy of data entry—no 
errors, contradictions or 
impossibilities in the data
 Absence of duplicates
Change in value of data filed by x% creates alerts
Variability of data values across common fields
Drop down menus, alerts, text prompts
Validate registry data sample (e.g. 10%) against source 
data
Software checks
Staff training
Help screens/desks
Funding for data managers
Completeness:
 Proportion of data missing
 Absence of core variables
Agreed % of fields completed in audit procedures 
(e.g. > 90%)
Proportion of patients lost to follow-up/attrition rates
Minimum agreed core common data elements reported
All treated patients reported, not selected patients only
Audits
Mandatory fields
Agreement on entry of ‘not done’ or ‘null’ values
Engagement with patients and HCPs
Agreed list of data elements and definitions
Cross-check patient numbers with numbers of products 
used at treating centres (applicable for some advanced 
therapies)
Box 1  Nature of the data collected and registry quality assurance processes
Workshop participants’ recommendations included:
 ‘Agree on standards for data quality indicators, terminologies/coding and reporting requirements to apply to national registries and to the ECF-
SPR’ (European Cystic Fibrosis Society Patient Registry) [17].
 ‘Agreement on the data elements to be collected in MS (multiple sclerosis) registries would facilitate treatment evaluations and comparisons of 
safety and effectiveness outcomes between different MS populations and across multiple countries’ [18].
 ‘Established quality standards should be in place and adequate for all registry studies; a dedicated data control and follow-up system should be 
introduced only for very specific studies or where the existing system is not [yet] adequate’ [19].
 ‘Definitions for the data elements required by the FVIII Guideline need to be agreed and applied across treating centres and registries; the 
associated data dictionaries need to be established and maintained’ [20].
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Marrow Transplant registry [19]. In both cases, the opinions 
describe contexts of use for which the registry data are con-
sidered suitable by CHMP for undertaking pharmacoepide-
miology studies. The possibility for registries to obtain sci-
entific advice to support a qualification opinion may go some 
considerable way in assuring stakeholders that registries so 
qualified are satisfactory for regulatory studies.
Internally, EMA has instituted measures to identify 
products during pre-submission stages of authorisation 
processes (pre-submission meetings, scientific advice and 
priority medicines [PRIME] discussions [28]) (Figure 1) 
where registry or other real world data may be needed for 
post-authorisation follow-up if marketing authorisation 
is granted. This action anticipates and permits pro-active 
planning for post-authorisation assessments and reflects 
the regulatory policy of benefit-risk assessment throughout 
the product lifecycle. To assist stakeholders in identifying 
potentially relevant registries, a publicly available inventory 
of patient registries is hosted on the European Network of 
Centres for Pharmacoepidemiology and Pharmacovigilance 
(ENCePP) resources database [29].
EMA should not duplicate other initiatives aiming to 
enhance registry use in healthcare. Therefore, its patient 
registries strategy aligns with the European Commission 
policy framework on rare diseases as well as with priorities 
of the European Research Networks for rare diseases, the 
Horizon 2020 programme and Joint Action initiatives such 
as the European Network for Health Technology Assess-
ment (EUnetHTA), and takes into account national endeav-
ours such as those underway in the Netherlands and Sweden 
[30–35]. The European Platform on Rare Diseases Registra-
tion (EU RD Platform) has developed a ‘Set of common data 
Table 3  Proposals on measures required for registry governance, informed consent, data protection and sharing
GDPR General Data Protection Regulation, MAA/MAH marketing authorisation applicant/holder
Topic Proposals for measures needed from stakeholders
Registry governance Regulators and/or MAAs/MAHs to identify early in the authorisation process whether a potentially relevant 
registry exists and identify data elements needed, especially for post-authorisation assessments likely to be 
requested or imposed, and to agree on a common study protocol.
Regulators and MAAs/MAHs to be aware of the data elements that can feasibly be collected systematically by 
relevant registries and to inform registries on their data needs.
Registry holders to establish a centralised data application process (with a standard template) for stakeholders 
to request and obtain data.
Communicate to patients and the public the benefits and uses of patient registry data and the value of high 
levels of patient inclusion in registries.
Informed consent Registry holders to ensure clinical/treating centres confirm that registry patients have provided consent and 
review whether current patient consent is broad enough for possible future situations taking into account 
European GDPR [24].
Data sharing and data protection Registry holders to develop a policy on data analysis and sharing summary, pseudo-anonymised, and indi-
vidual patient data that aligns with national regulation and European GDPR.
Box 2  Registry governance, informed consent, data protection and sharing
Workshop participants’ recommendations included:
 Registry holders need to optimise communications with patients, MAHs, and regulators by: informing patients on the benefits and uses of 
patient registry data including appropriate sharing with relevant stakeholders and by informing MAHs and regulators of the type and detail of 
registry data that may feasibly be shared within consent and governance parameters’ [17].
 Standing agreements between MAHs and registry holders could facilitate provision of data for regulatory procedures, either routine (e.g., peri-
odic safety update reports (PSURs), or exceptional (e.g., during a referral procedure) [18].
 Data analysis should preferably be performed by the registry owner or by a third-party (e.g. academic centre, contract research organisation) 
rather than by MAHs/MAAs. If data analysis is conducted by the registry holder or a third party, results of product-specific data analysis 
should be shared with regulators and the concerned MAHs/MAAs in line with provisions of the study protocol’ [19].
 Prior to commencing imposed studies, transparent arrangements should be in place for sharing and publishing data and results’ [19].
 Registries should take a central role in working with their affiliated treating centres to harmonise patient consents ensuring they are aligned 
with the GDPR as well as with national requirements allowing sharing of aggregated and anonymised patient-level data for research or regu-
latory purposes’ [20].
 Specific protocols need to be sufficiently detailed as to allow registries to assess whether they can participate (in terms of data availability and 
quality)’ [20].
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elements for RD Registration’ [36]. It is aimed at the Euro-
pean Reference Network’s existing registries and registries 
under development; other rare disease registries at national, 
regional, and local levels in EU Member States; researchers 
and patient organisations.
From a regulatory perspective, the ultimate requirement 
of patient registries is that they permit the conduct of high-
quality studies that evaluate the safety and effectiveness of 
medicines. Recognising the benefits and challenges inher-
ent in using observational data for medicines assessments, 
in 2019, EMA will publish methodological and operational 
advice on handling registry data in post-authorisation stud-
ies, taking into account responses to its open consultation 
on a preliminary discussion paper [6]. Application of the 
advice will be underpinned by clear understanding of the 
differences between a registry and a registry study (Table 4).
7  Conclusions
This is the first time that the factors necessary for patient 
registry data to adequately support regulatory assessments, 
together with operational proposals required for their imple-
mentation, have been set out explicitly from a regulatory 
perspective. In explaining what is needed, taking account 
of the current legal and regulatory framework for medicinal 
products, the proposals empower stakeholders seeking to 
capitalise on the potential of patient registries broadly to 
Fig. 1  Opportunities during the regulatory cycle to identify where registry data may be needed for post-authorisation follow-up. Source: Clin 
Pharmacol Ther 2019 https ://doi.org/10.1002/cpt.1414
Box 3  Stakeholder communication and planning of benefit-risk assessments
Workshop participants’ recommendations included:
 Communicate the value of registries, their limitations, and the importance of consistent data quality to all participating healthcare professionals 
and to those using the data including MAHs, regulators, HTA and reimbursement bodies’ [17].
 MAHs, regulators and registry holders, plus other stakeholders where relevant (for example, reimbursement bodies), should engage in discus-
sions early during the regulatory processes for approval of new treatments to consider data needs and scientific / study protocols and to 
understand the range and nature of data that registries could provide, especially for post-authorisation studies’ [18].
 MAHs / MAAs need to ‘commence planning for post-authorisation data collection early in product development’ and ‘develop a preliminary 
study protocol and explore with the registry holder/s and regulators if the registry could fulfil the data needs, for example, through a scientific 
advice procedure’ [19].
 MAAs must ‘[i]nitiate discussions with registries and regulators before or at an early stage of a marketing authorisation application on the 
relevance and adequacy of one or several existing disease registries for the long-term monitoring of their specific product’ [20].
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support and contribute to regulatory decision-making on 
medicines.
Actions by all stakeholders, registry owners as well as 
MAAs/MAHs, regulators, patients/their representatives, 
healthcare professionals, and HTA and medicines reim-
bursement bodies, are required to implement the proposals 
and thereby consolidate registry value in patient and public 
health.
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